Mirum Pharmaceuticals, Inc.
MIRM
$43.45
$0.912.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 42.93% | 89.37% | 107.68% | 119.07% | 149.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.93% | 89.37% | 107.68% | 119.07% | 149.24% |
| Cost of Revenue | -8.95% | 103.42% | 196.93% | 258.10% | 456.74% |
| Gross Profit | 72.08% | 85.54% | 87.87% | 93.07% | 90.22% |
| SG&A Expenses | 23.05% | 38.37% | 49.35% | 51.02% | 74.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.05% | 41.43% | 65.30% | 62.89% | 64.56% |
| Operating Income | 25.67% | 49.56% | 0.17% | 2.50% | 4.61% |
| Income Before Tax | 31.24% | 40.49% | 67.44% | 17.62% | 2.36% |
| Income Tax Expenses | -356.00% | 39.36% | 100.95% | 210.45% | 60.71% |
| Earnings from Continuing Operations | 33.28% | 39.65% | 66.72% | 16.10% | 2.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.28% | 39.65% | 66.72% | 16.10% | 2.12% |
| EBIT | 25.67% | 49.56% | 0.17% | 2.50% | 4.61% |
| EBITDA | 32.94% | 70.52% | 19.88% | 19.40% | 17.81% |
| EPS Basic | 42.60% | 48.09% | 73.15% | 32.64% | 18.99% |
| Normalized Basic EPS | -253.72% | 48.80% | 21.43% | 33.86% | 131.11% |
| EPS Diluted | 42.80% | 48.09% | 73.15% | 32.64% | 19.88% |
| Normalized Diluted EPS | -253.72% | 48.80% | 21.43% | 33.86% | 131.24% |
| Average Basic Shares Outstanding | 16.23% | 16.26% | 23.95% | 24.56% | 20.82% |
| Average Diluted Shares Outstanding | 16.23% | 16.26% | 23.95% | 24.56% | 20.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |